Search Contract Opportunities

Lenalidomide   3

ID: 36C25226Q0112 • Type: Solicitation • Match:  95%
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Please sign-in to link federal registration and award history to assistant. Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Do the documents mention an incumbent contractor?
I'd like to anonymously submit a question to the procurement officer(s)
Loading

Description

Posted: Dec. 1, 2025, 1:42 p.m. EST
This amendment hereby changes the date for which responses are due from 12/1/2025 at 3:00 p.m. CST to 12/3/2025 at 3:00 p.m. CST. All other terms and conditions remain in effect.
Posted: Nov. 21, 2025, 10:17 a.m. EST
Background
The Department of Veterans Affairs is seeking to procure Lenalidomide, also known by its brand name Revlimid, for the Jesse Brown VA Medical Center's Pharmacy Service Department. This medication is used to treat various conditions including multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The contract aims to ensure that veterans receive necessary medications in compliance with the Lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program, which restricts distribution to certified pharmacies only.

Work Details
The contract includes the delivery of Lenalidomide capsules in various dosages as follows:
1. LENALIDOMIDE 2.5MG ORAL CAP - Quantity: 924
2. LENALIDOMIDE 5MG ORAL CAP - Quantity: 1572
3. LENALIDOMIDE 10MG ORAL CAP - Quantity: 2674
4. LENALIDOMIDE 15MG ORAL CAP - Quantity: 252
5. LENALIDOMIDE 20MG ORAL CAP - Quantity: 252
6. LENALIDOMIDE 25MG ORAL CAP - Quantity: 252

The contractor must ensure that all prescriptions are dispensed according to the REMS requirements and delivered to the Jesse Brown VA Medical Center located at 820 South Damen Avenue, Chicago, IL.

Period of Performance
12 months after the award

Place of Performance
Jesse Brown VA Medical Center, Pharmacy Services located at 820 South Damen Ave, Chicago, IL.

Overview

Response Deadline
Dec. 3, 2025, 4:00 p.m. EST (original: Dec. 1, 2025, 4:00 p.m. EST) Past Due
Posted
Nov. 21, 2025, 10:17 a.m. EST (updated: Dec. 1, 2025, 1:42 p.m. EST)
Set Aside
None
Place of Performance
820 South Damen Ave Chicago, IL USA
Source

Current SBA Size Standard
1300 Employees
Pricing
Likely Fixed Price
Est. Level of Competition
Average
Est. Value Range
Experimental
$50,000 - $250,000 (AI estimate)
On 11/21/25 VISN 12: Great Lakes Health Care System issued Solicitation 36C25226Q0112 for Lenalidomide due 12/3/25. The opportunity was issued full & open with NAICS 325412 and PSC 6505.
Primary Contact
Title
Contract Specialist
Name
James (Jim) R Hedman   Profile
Phone
None

Additional Contacts in Documents

Title Name Email Phone
Contract Specialist Arneil Genus Profile arneil.genus@va.gov None

Documents

Posted documents for Solicitation 36C25226Q0112

Question & Answer

The AI Q&A Assistant has moved to the bottom right of the page

Opportunity Lifecycle

Procurement notices related to Solicitation 36C25226Q0112

Award Notifications

Agency published notification of awards for Solicitation 36C25226Q0112

Contract Awards

Prime contracts awarded through Solicitation 36C25226Q0112

Incumbent or Similar Awards

Contracts Similar to Solicitation 36C25226Q0112

Potential Bidders and Partners

Awardees that have won contracts similar to Solicitation 36C25226Q0112

Similar Active Opportunities

Open contract opportunities similar to Solicitation 36C25226Q0112

Experts for Lenalidomide

Recommended subject matter experts available for hire

Additional Details

Source Agency Hierarchy
VETERANS AFFAIRS, DEPARTMENT OF > VETERANS AFFAIRS, DEPARTMENT OF > 252-NETWORK CONTRACT OFFICE 12 (36C252)
FPDS Organization Code
3600-0069D
Source Organization Code
100180018
Last Updated
Dec. 1, 2025
Last Updated By
james.hedman2@va.gov
Archive Date
Jan. 2, 2026